Gut microbiome modulates tacrolimus pharmacokinetics through the transcriptional regulation of ABCB1

[1]  Wei Zhang,et al.  Antibiotics-Induced Depletion of Rat Microbiota Induces Changes in the Expression of Host Drug-Processing Genes and Pharmacokinetic Behaviors of CYPs Probe Drugs , 2023, Drug Metabolism and Disposition.

[2]  Ethan Loew,et al.  Microbial Metabolites Orchestrate a Distinct Multi-Tiered Regulatory Network in the Intestinal Epithelium That Directs P-Glycoprotein Expression , 2022, mBio.

[3]  C. Prado,et al.  Rethinking healthy eating in light of the gut microbiome. , 2022, Cell host & microbe.

[4]  Xiaowei Xu,et al.  Bacillus subtilis plays a role in the inhibition of transporter ABCB1 in Caco-2 cells , 2022, Epilepsy Research.

[5]  A. Israni,et al.  OPTN/SRTR 2020 Annual Data Report: Kidney , 2022, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[6]  Luis Pedro Coelho,et al.  Combinatorial, additive and dose-dependent drug–microbiome associations , 2021, Nature.

[7]  N. Chattipakorn,et al.  Impact of gut microbiota on kidney transplantation. , 2021, Transplantation reviews.

[8]  D. Ward,et al.  Gut microbiota regulation of P-glycoprotein in the intestinal epithelium in maintenance of homeostasis , 2021, Microbiome.

[9]  D. Ward,et al.  Gut microbiota regulation of P-glycoprotein in the intestinal epithelium in maintenance of homeostasis , 2021, Microbiome.

[10]  Mark S. Sundrud,et al.  CAR directs T cell adaptation to bile acids in the small intestine , 2021, Nature.

[11]  T. Fujita,et al.  Characterization of P-Glycoprotein Inhibitors for Evaluating the Effect of P-Glycoprotein on the Intestinal Absorption of Drugs , 2021, Pharmaceutics.

[12]  Patrice D Cani,et al.  Multi‐compartment metabolomics and metagenomics reveal major hepatic and intestinal disturbances in cancer cachectic mice , 2021, Journal of cachexia, sarcopenia and muscle.

[13]  G. Tsiamis,et al.  Impact of the Post-Transplant Period and Lifestyle Diseases on Human Gut Microbiota in Kidney Graft Recipients , 2020, Microorganisms.

[14]  Hyunyoung Jeong,et al.  Blood Profiles of Gut Bacterial Tacrolimus Metabolite in Kidney Transplant Recipients , 2020, Transplantation direct.

[15]  V. Haufroid,et al.  Predictors of tacrolimus pharmacokinetic variability: current evidences and future perspectives , 2020, Expert opinion on drug metabolism & toxicology.

[16]  Bahar Javdan,et al.  Personalized Mapping of Drug Metabolism by the Human Gut Microbiome , 2020, Cell.

[17]  D. DuBay,et al.  A comprehensive review of the impact of tacrolimus intrapatient variability on clinical outcomes in kidney transplantation , 2020, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[18]  Jingyuan Fu,et al.  Interaction between drugs and the gut microbiome , 2020, Gut.

[19]  Zhaoli Sun,et al.  Butyric acid normalizes hyperglycemia caused by the tacrolimus‐induced gut microbiota , 2020, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[20]  S. Kapur,et al.  Identification of Antibiotic Administration as a Potentially Novel Factor Associated With Tacrolimus Trough Variability in Kidney Transplant Recipients: A Preliminary Study , 2019, Transplantation direct.

[21]  A. Goodman,et al.  Mapping human microbiome drug metabolism by gut bacteria and their genes , 2019, Nature.

[22]  B. Guida,et al.  Nutritional management in renal transplant recipients: A transplant team opportunity to improve graft survival. , 2019, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[23]  Y. Lixin,et al.  [Gut microbiota in renal transplant recipients, patients with chronic kidney disease and healthy subjects]. , 2018, Nan fang yi ke da xue xue bao = Journal of Southern Medical University.

[24]  John Macsharry,et al.  Gut Microbiota-Mediated Bile Acid Transformations Alter the Cellular Response to Multidrug Resistant Transporter Substrates in Vitro: Focus on P-glycoprotein. , 2018, Molecular pharmaceutics.

[25]  Hyunyoung Jeong,et al.  Commensal Gut Bacteria Convert the Immunosuppressant Tacrolimus to Less Potent Metabolites , 2018, Drug Metabolism and Disposition.

[26]  Q. Zhang,et al.  Immunosuppressive effect of the gut microbiome altered by high‐dose tacrolimus in mice , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[27]  N. Kamar,et al.  High tacrolimus intra-patient variability is associated with graft rejection, and de novo donor-specific antibodies occurrence after liver transplantation , 2018, World journal of gastroenterology.

[28]  C. Klaassen,et al.  RNA-Seq Profiling of Intestinal Expression of Xenobiotic Processing Genes in Germ-Free Mice , 2017, Drug Metabolism and Disposition.

[29]  Jean M. Macklaim,et al.  Microbiome Datasets Are Compositional: And This Is Not Optional , 2017, Front. Microbiol..

[30]  R. Kukreti,et al.  In Vitro Assessment of the Effect of Antiepileptic Drugs on Expression and Function of ABC Transporters and Their Interactions with ABCC2 , 2017, Molecules.

[31]  C. Holt.  Overview of Immunosuppressive Therapy in Solid Organ Transplantation. , 2017, Anesthesiology clinics.

[32]  H. Colom,et al.  The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation , 2017, Pharmacogenetics and genomics.

[33]  A. Lupo,et al.  Impact of maintenance immunosuppressive therapy on the fecal microbiome of renal transplant recipients: Comparison between an everolimus- and a standard tacrolimus-based regimen , 2017, PloS one.

[34]  A. Rostami-Hodjegan,et al.  Caco‐2 cells – expression, regulation and function of drug transporters compared with human jejunal tissue , 2017, Biopharmaceutics & drug disposition.

[35]  Robert C. Edgar,et al.  UNOISE2: improved error-correction for Illumina 16S and ITS amplicon sequencing , 2016, bioRxiv.

[36]  V. Haufroid,et al.  Pharmacogenetic-based strategy using de novo tacrolimus once daily after kidney transplantation: prospective pilot study. , 2016, Pharmacogenomics.

[37]  Peter J. Turnbaugh,et al.  The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism , 2016, Nature Reviews Microbiology.

[38]  Jens Roat Kultima,et al.  Disentangling the effects of type 2 diabetes and metformin on the human gut microbiota , 2016 .

[39]  C. Klaassen,et al.  Review: Mechanisms of How the Intestinal Microbiota Alters the Effects of Drugs and Bile Acids , 2015, Drug Metabolism and Disposition.

[40]  F. Carvalho,et al.  Modulation of P-glycoprotein efflux pump: induction and activation as a therapeutic strategy. , 2015, Pharmacology & therapeutics.

[41]  D. Hesselink,et al.  Intra-patient variability in tacrolimus exposure: causes, consequences for clinical management. , 2015, Transplantation reviews.

[42]  Nora C. Toussaint,et al.  Gut Microbiota and Tacrolimus Dosing in Kidney Transplantation , 2015, PloS one.

[43]  Nora C. Toussaint,et al.  Gut Microbial Community Structure and Complications After Kidney Transplantation: A Pilot Study , 2014, Transplantation.

[44]  Sandhya Kortagere,et al.  Symbiotic Bacterial Metabolites Regulate Gastrointestinal Barrier Function via the Xenobiotic Sensor PXR and Toll‐like Receptor 4 , 2014, Immunity.

[45]  V. Haufroid,et al.  ABCB1 1199G>A Genetic Polymorphism (Rs2229109) Influences the Intracellular Accumulation of Tacrolimus in HEK293 and K562 Recombinant Cell Lines , 2014, PloS one.

[46]  F. Marincola,et al.  Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment , 2013, Science.

[47]  S. Yamashita,et al.  In Vivo Assessment of the Impact of Efflux Transporter on Oral Drug Absorption Using Portal Vein–Cannulated Rats , 2013, Drug Metabolism and Disposition.

[48]  J. Barrett,et al.  Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis , 2013, Pharmacogenetics and genomics.

[49]  V. Tremaroli,et al.  Analysis of gut microbial regulation of host gene expression along the length of the gut and regulation of gut microbial ecology through MyD88 , 2011, Gut.

[50]  L. Meza-Zepeda,et al.  Depletion of Murine Intestinal Microbiota: Effects on Gut Mucosa and Epithelial Gene Expression , 2011, PloS one.

[51]  E. Want,et al.  Colonization-Induced Host-Gut Microbial Metabolic Interaction , 2011, mBio.

[52]  M. Mikov,et al.  Clinical pharmacokinetics of tacrolimus after the first oral administration in renal transplant recipients on triple immunosuppressive therapy. , 2010, Basic & clinical pharmacology & toxicology.

[53]  J. Teuteberg,et al.  Elevated tacrolimus levels associated with intravenous azithromycin and ceftriaxone: a case report. , 2010, Transplantation proceedings.

[54]  K. Yoshinari,et al.  Involvement of Vitamin D Receptor in the Intestinal Induction of Human ABCB1 , 2009, Drug Metabolism and Disposition.

[55]  K. Watanabe,et al.  Intestinal flora induces the expression of Cyp3a in the mouse liver , 2009, Xenobiotica; the fate of foreign compounds in biological systems.

[56]  S. Urien,et al.  Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients. , 2007, British journal of clinical pharmacology.

[57]  R. Evans,et al.  Anatomical Profiling of Nuclear Receptor Expression Reveals a Hierarchical Transcriptional Network , 2006, Cell.

[58]  A. Ungell,et al.  Variability in mRNA expression of ABC- and SLC-transporters in human intestinal cells: comparison between human segments and Caco-2 cells. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[59]  Y. H. Chen,et al.  Clinical pharmacokinetics of tacrolimus after the first oral administration in combination with mycophenolate mofetil and prednisone in Chinese renal transplant recipients. , 2005, Transplantation proceedings.

[60]  P. Rutgeerts,et al.  Cytochrome P450 3A4 and P‐glycoprotein Activity and Assimilation of Tacrolimus in Transplant Patients with Persistent Diarrhea , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[61]  S. Satomi,et al.  Severe elevations of FK506 blood concentration due to diarrhea in renal transplant recipients , 2004, Clinical transplantation.

[62]  T. Willson,et al.  The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[63]  C. Baird,et al.  The pilot study. , 2000, Orthopedic nursing.

[64]  N. Undre,et al.  The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[65]  L. Forney,et al.  Distribution of bacterioplankton in meromictic Lake Saelenvannet, as determined by denaturing gradient gel electrophoresis of PCR-amplified gene fragments coding for 16S rRNA , 1997, Applied and environmental microbiology.

[66]  T. Starzl,et al.  Clinical Pharmacokinetics of Tacrolimus , 1995, Clinical pharmacokinetics.

[67]  Y. Tanigawara,et al.  Human P-glycoprotein transports cyclosporin A and FK506. , 1993, The Journal of biological chemistry.

[68]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[69]  A. Dantzig,et al.  Reversal of multidrug resistance by the P-glycoprotein modulator, LY335979, from the bench to the clinic. , 2001, Current medicinal chemistry.

[70]  K. Iwasaki,et al.  Further metabolism of FK506 (tacrolimus). Identification and biological activities of the metabolites oxidized at multiple sites of FK506. , 1995, Drug metabolism and disposition: the biological fate of chemicals.